KC 764

Drug Profile

KC 764

Latest Information Update: 14 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyorin Pharmaceutical
  • Class Anti-ischaemics; Antiplatelets; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Intracranial thrombosis; Ischaemic heart disorders; Thrombosis; Transient ischaemic attacks

Most Recent Events

  • 31 Mar 1995 Phase-III clinical trials for Thrombosis in Japan (Unknown route)
  • 07 Nov 1994 Phase-II clinical trials for Transient ischaemic attacks in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top